LITERATURE REVIEW
Internal Medicine
doi: 10.25005/2074-0581-2024-26-2-284-293
EFFECTS OF MELATONIN ON BLOOD PRESSURE IN THE ELDERLY

F.D. BOBOEV1, R.G. SOKHIBOV1, SH.F. ODINAEV2, A.A. UMAROV1, SH.A. SULAYMONOVA1

1Department of Internal Diseases № 2, Avicenna Tajik State Medical University, Dushanbe, Republic of Tajikistan
2Department of Internal Diseases № 1, Avicenna Tajik State Medical University, Dushanbe, Republic of Tajikistan

The study provides literature data on the impact of melatonin on blood pressure (BP) in elderly individuals with arterial hypertension (AH). AH is a significant risk factor for cardiovascular diseases (CVDs) and is a key focus of medical research. Melatonin, which plays a crucial role in the body's regulatory mechanisms, particularly when its production is disrupted, can significantly influence the development of AH. Melatonin is not a specific treatment for a particular disease but a multifunctional element that helps maintain homeostasis. Combining melatonin with antihypertensive therapy in elderly individuals with AH has been found to lead to more effective treatment outcomes. Exploring the effects of melatonin on BP levels in elderly individuals with AH is of great scientific interest, especially in understanding the relationship between individual melatonin secretion characteristics and predisposition to cardiovascular complications. This topic requires further research for a deeper understanding. Over 400 sources were analyzed on various aspects of the impact of melatonin on BP levels using materials from the PubMed and Google Scholar electronic databases. Out of these, 44 sources were selected and included in the study, considering relevant keywords.

Keywords: Melatonin, blood pressure, arterial hypertension, cardiovascular disease, old age.

Download file:

References
  1. Chazova IE, Oshchepkova EV, Zhernakova YuV. Diagnostika i lechenie arterial'noy gipertonii. Klinicheskie rekomendatsii 2013 g [Diagnosis and treatment of arterial hypertension. 2013 Clinical Guidelines]. Cardiologicheskiy vestnik. 2015;1:3-30.
  2. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. Task Force Members. 2016 European Guideline son cardiovascular disease prevention in clinical practice. European Heart J. 2016;37(29):2315-81. https://doi. org/10.1093/eurheart/ehw106
  3. Budnevskiy AV, Ovsyannikov ES, Rezova NV, Shkatova JaS. Melatonin i arterial'naya gipertoniya: vozmozhnaya rol' v kompleksnoy terapii [Melatonin and arterial hypertension: Possible role in complex therapy]. Terapevticheskiy arkhiv. 2017;89(12):122-6. https://doi.org/10.17116/terarkh20178912122-126
  4. Foy AJ, Mandrola JM. Heavy Heart: The economic burden of heart disease in the United States Now and in the future. Prim Care. 2018;45(1):17-24. https:// doi.org/10.1016/j.pop.2017.11.002
  5. Chow CK, Teo KK, Rangarajan S, Islam M, Zhang S, Kabali M, Dehghan J, et al. PURE Study Investigators. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA. 2013;310:959-68. https://doi.org/10.1001/ jama.2013.184182
  6. Williams B, Mancia G, Spiering W, Agabiti RE, Azizi M, Burner M, et al. ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). European Heart J. 2018;39(33):3021-104. https://doi. org/10.1093/eurheartj/ehy339
  7. Khirmanov VN. Aktual'nye voprosy vedeniya patsientov s gipertonicheskimi krizami [Topical issues of management of patients with hypertensive crises]. Neotlozhnaya kardioilogiya i kardiovasculyarnye riski. 2018;2(2):312-22.
  8. Chazova IE, Zhernakova YuV. on behalf of experts. Klinicheskie rekomendatsii. Diagnostika i lechenie arterial'noĭ gipertonii [Clinical guidelines. Diagnosis and treatment of arterial hypertension]. Sistemnye gipertenzii. 2019;16(1):6-31. https://doi.org/10.26442/2075082X.2019.1.190179
  9. Briasoulis A, Agarwal V, Tousoulis D, Stefanadis C. Effects of antihypertensive treatment in patients over 65 years of age: A meta-analysis of randomized controlled studies. Heart. 2014;100:317-23. https://doi.org/10.1136/heartjnl-2013-304111
  10. Smolensky MH, Hermida RC, Portaluppi F. Circadian mechanisms of 24-hour blood pressure regulation and patterning. Sleep Med Rev. 2017;33:4-16. https://doi.org/10.1016/j.smrv.2016.02.003
  11. Hermida RC, Ayala DE, Mojón A, Fernández JR. Sleep-time ambulatory BP is an independent prognostic marker of CKD. J Am Soc Nephrol. 2017;28(9):2802-11. https://doi.org/10.1681/ASN.2016111186
  12. Turek FW. Circadian clocks: Not your grandfather’s clock. Science. 2016;354(6315):992-3. https://doi.org/10.1126/science.aal2613
  13. Ettehad D, Emdin CA, Kiran A, Anderson S, Callender T, Emberson J, Rodgers A, еt al. Blood pressure lowering for prevention of cardiovascular disease and death: A systematic review and meta-analysis. Lancet. 2016;387(10022):957- 67. https://doi.org/10.1016/S0140-6736 (15)01225-8
  14. Luo Y, Wang YL, Wu YB, Xu Y, Liang YL, Barry M, et al. Association between the rate of the morning surge in blood pressure and cardiovascular events and stroke. Chin Med J (Engl.). 2013;126(3):510-4.
  15. Agadzhanyan NA, Radysh IV. Bioritmy. Sreda obitaniya [Biorhythms. Habitat]. Moscow, RF: Zdorov'e; 2013. 362 p.
  16. Pati P, Fulton DJ, Bagi Z, Chen F, Wang Y, Kitchens J, et al. Low-salt diet and circadian dysfunction synergize to induce angiotensin II-dependent hypertension in mice. Hypertension. 2016;67(3):661-8. https://doi.org/10.1161/HYPERTENSIONAHA.115.06194
  17. Fujiwara T, Tomitani N, Sato K, Okura A, Suzuki N, Kario K. The relationship between a blunted morning surge and a reversed nocturnal blood pressure dipping or "riser" pattern. J Clin Hypertens (Greenwich). 2017;19(11):1108-14.
  18. Douma LG, Gumz ML. Circadian clock-mediated regulation of blood pressure. Free Radic Biol Med. 2018;119:108-14. https://doi.org/10.1016/J.FREERADBIOMED.2017.11.024
  19. Budnevskiy AV, Ovsyannikov ES, Filina NV. Rol' melatonina v patogeneze serdechno-sosudistykh zabolevaniy [The role of melatonin in the pathogenesis of cardiovascular diseases]. Kardiovaskulyarnaya terapiya i profilaktika. 2016;5:97-101. https://doi.org/10.15829/1728-8800-2016-5-97-101
  20. Hunter CM, Figueiro MG. Measuring light at night and melatonin levels in shift workers: A review of the literature. Biol Res Nurs. 2017;19(4):365-74. https:// doi.org10.1177/1099800417714069
  21. Amaral FGD, Cipolla-Neto J. A brief review about melatonin, a pineal hormone. Arch Endocrinol Metab. 2018;62(4):472-9. https://doi.org/10.20945/2359- 3997000000066
  22. Tosches MA, Bucher D, Vopalensky P, Arendt D. Melatonin signaling controls circadian swimming behavior in marine zooplankton. Cell. 2014;159(1):46-57. https://doi.org/10.1016/j.cell.2014.07.042
  23. Nduhirabandi F, Maarman GJ. Melatonin in heart failure: A promising therapeutic strategy. Molecules. 2018;23(7):1819. https://doi.org/10.3390/molecules23071819
  24. Zaslavskaya RM, Shcherban EA, Kelimberdieva ES. Melatonin (melaksen) kak adaptogen pri meteorologicheskoy i geomagnitnoy zavisimosti u patsientov s arterial'noy gipertoniey i ishemicheskoy bolezn'yu serdtsa [Melatonin (melaxen) as an adaptogen for meteorological and geomagnetic dependence in patients with arterial hypertension and coronary heart disease]. The Scientific Heritage. 2023;105:50-2
  25. Zhang M, Lin J, Wang S, Cheng Z, Hu J, Wang T, Man W, Yin T, et al. Melatonin protects against diabetic cardiomyopathy through Mst1.Sirt3 signaling. J Pineal Res. 2017;63(2). https://doi.org/10.1111/jpi.12418
  26. Baker J, Kimpinski K. Role of melatonin in blood pressure regulation: An adjunct anti-hypertensive agent. Clin Exp Pharmacol Physiol. 2018;45(8):755-66. https://doi.org/10.1111/1440-1681.12942
  27. Jiki Z, Lecour S, Nduhirabandi F. Cardiovascular benefits of dietary melatonin: A myth or a reality. Front Physiol. 2018;9:528. https://doi.org/10.3389/ fphys.2018.00528
  28. Simko F, Baka T, Paulis L, Reiter RJ. Elevated heart rate and nondipping heart rate as potential targets for melatonin: A review. J Pineal Res. 2016;61(2):127- 37. https://doi.org/10.1111/jpi.12348
  29. Zaslavskaya RM, Kelimberdieva ES, Teyblyum MM. Obosnovanie primeneniya melatonina pri arterial'noy gipertonii i ishemicheskoy bolezni serdtsa [Rationale for the use of melatonin in arterial hypertension and coronary heart disease]. The Scientific Heritage. 2021;69:15-22.
  30. Palman AD, Rapoport SI. Melatonin i arterial'naya gipertenziya [Melatonin and arterial hypertension]. Effektivnaya farmakoterapiya. 2014;22:64-71.
  31. Zaslavskaya RM, Shcherban EA, Teyblyum MM. Melatonin v kardiologii i khronomeditsine [Melatonin in cardiology and chronomedicine]. Moscow, RF: Medpraktika-M; 2019. 166 p.
  32. Kario K. Are melatonin and its receptor agonist specific antihypertensive modulators of resistant hypertension caused by disrupted circadian rhythm. J Am Soc Hypertens. 2011;5(5):354-8. https://doi.org/10.1016/j.jash.2011.03.006
  33. Demirdaş A, Nazıroğlu M, Unal GO. Agomelatine reduces brain, kidney and liver oxidative stress but increases plasma cytokine production in the rats with chronic mild stress-induced depression. Meta Brain Dis. 2016;31(6):1445-53. https://doi.org/10.1007/s11011-016-9874-2
  34. Mendel VE, Mendel OI. Melatonin: rol' v organizme i terapevticheskie vozmozhnosti. Opyt primeneniya preparata Melaksen v meditsinskoy praktike [Melatonin: role in the body and therapeutic possibilities. Experience of using the drug Melaxen in medical practice]. RMZH. 2010;6:336
  35. Zaslavskaya RM, Shcherban EA, Teyblyum MM. Gendernye razlichiya v effektivnosti gipotenzivnoy terapii s vklyucheniem melatonina bol'nykh arterial'noy gipertoniey i ishemicheskoy bolezn'yu serdtsa [Gender differences in the effectiveness of antihypertensive therapy with the inclusion of melatonin in patients with arterial hypertension and coronary heart disease]. Annali d'Italia. 2021;20:30-5.
  36. Obayashi K, Saeki K, Tone N, Kurumatani N. Relationship between melatonin secretion and nighttime blood pressure in elderly individuals with and without antihypertensive treatment: A cross-sectional study of the HEIJO-KYO cohort. Hypertens Res. 2014;37(10):908-13. https://doi.org/10.1038/hr.2014.99
  37. Huang L, Zhang C, Hou Y, Laudon M, She M, Yang S, et al. Blood pressure reducing effects of piromelatine and melatonin in spontaneously hypertensive rats. Eur Rev Med Pharmacol Sci. 2013;17:2449-56.
  38. Mozdzan M, Mozdzan M, Chalubinski M, Wojdan K, Broncel M. The effect of melatonin on circadian blood pressure in patients with type 2 diabetes and essential hypertension. Arch Med Sci. 2014;10(4):669-75. https://doi. org/10.5114/aoms.2014.44858
  39. Nedogoda SV, Smirnova VO, Barykina IN, Salasyuk AS, Khripaeva VYu, Palashkin RV, i dr. Vliyanie terapii preparatom melatonina na funktsiyu endoteliya, arterial'noe davlenie i sosudistuyu zhyostkost' u patsientov s metabolicheskim sindromom i narusheniyami sna [The effect of melatonin therapy on endothelial function, blood pressure and vascular stiffness in patients with metabolic syndrome and sleep disorders]. Arterial’naya gipertensiya. 2017;23(2):15-59. https://doi.org/10.18705/1607-419X-2017-23-2-150-159
  40. Raygan F, Ostadmohammadi V, Bahmani F, Reiter RJ, Asemi Z. Melatonin administration lowers biomarkers of oxidative stress and cardio-metabolic risk in type 2 diabetic patients with coronary heart disease: A randomized, double-blind, placebo-controlled trial. Clin Nutr. 2019;38(1):191-6. https://doi. org/10.1016/j.clnu.2017/12/004
  41. Belyakov VI, Kuchin SS, Chernyshov VN, Antipov EV. Sravnitel'noe vliyanie melatonina i agomelatine na parametry krovoobrashcheniya [Comparative effects of melatonin and agomelatine on circulatory parameters]. Vestnik meditsinskogo instituta «REAVIZ»: reabilitatsiya, vrachi zdorov'e. 2017;6:213-8.
  42. Klimentova J, Cebova M, Barta A, Matuskova Z, Vrankova S, Rehakova R, et al. Effect of melatonin on blood pressure and nitric oxide generation in rats with metabolic syndrome. Physiol Res. 2016;65(3):373-80. https://doi. org/10.33549/physiolres.933436
  43. Maarman G, Blackhurst D, Thienemann F, Blauwet L, Butrous G, Davies N, et al. Melatonin as a preventive and curative therapy against pulmonary hypertension. J Pineal Res. 2015;59:343-53. https://doi.org/10.1111/jpi.12263
  44. Gubin DG, Vaynert D, Solovyova SV, Durov AM. Rol' aktivnosti, sna i vneshney osveshchyonnosti v sutochnoy dinamike arterial'nogo davleniya [The role of activity, sleep and external illumination in the daily dynamics of blood pressure]. Meditsinskiy alfavit. 2018;3:20-3.

Authors' information:

Boboev Firdavs Davronovich,
PhD Student, Department of Internal Diseases № 2, Avicenna Tajik State Medical University
ORCID ID: 0000-0001-5773-6914
SPIN: 3172-2585
E-mail: fredi-tj@mail.ru

Sokhibov Rakhmatullo Gulyamovich,
Candidate of Medical Sciences, Associate Professor, Head of the Department of Internal Diseases № 2, Avicenna Tajik State Medical University
ORCID ID: 0000-0002-2413-9299
E-mail: sohibov.rahmatullo@mail.ru

Odinaev Shukhrat Farkhodovich,
Doctor of Medical Sciences, Associate Professor, Head of the Department of Internal Diseases № 1, Avicenna Tajik State Medical University
ORCID ID: 0000-0002-4188-5955
E-mail: nnnn70@mail.ru

Umarov Akhmed Abubakirovich,
Candidate of Medical Sciences, Associate Professor, Associate Professor of the Department of Internal Diseases № 2, Avicenna Tajik State Medical University
ORCID ID: 0009-0007-2719-7957
E-mail: ahmad.umarov@bk.ru

Sulaymonova Shakhrikhon Amonovna,
Candidate of Medical Sciences, Assistant of the Department of Internal Diseases № 2, Avicenna Tajik State Medical University
ORCID ID: 0009-0009-7737-5154
E-mail: cardiology64@mail.ru

Information about support in the form of grants, equipment, medications

The authors did not receive financial support from manufacturers of medicines and medical equipment

Conflicts of interest: No conflict

Address for correspondence:

Boboev Firdavs Davronovich
PhD Student, Department of Internal Diseases № 2, Avicenna Tajik State Medical University

734026, Republic of Tajikistan, Dushanbe, Sino str., 29-31

Теl.: +992 (918) 449691

E-mail: fredi-tj@mail.ru

Materials on the topic:
  1. COMPLIANCE AND QUALITY OF LIFE OF PATIENTS WITH INFLAMMATORY BOWEL DISEASES
  2. PSYCHOCOGNITIVE STATUS OF PATIENTS WITH ARTERIAL HYPERTENSION COMBINED WITH POST-COVID SYNDROME
  3. GASTROINTESTINAL MOTOR FUNCTION IN GERIATRIC PATIENTS WITH TYPE 2 DIABETES MELLITUS UNDERGOING JOINT REPLACEMENT
  4. THE EFFECTIVENESS OF OZONE THERAPY FOR ARTERIAL HYPERTENSION AND CONCOMITANT GASTROPATHY IN MINERS
  5. EVALUATION OF VENTILATION-PERFUSION RATIO IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE
  6. RELATIONSHIP OF THE STATE OF BIOMEMBRANES WITH INDICATORS OF ENDOTHELIUM DYSFUNCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
  7. SCREENING OF RISK FACTORS OF CHRONIC NON-COMMUNICABLE DISEASES AMONG POPULATION OF THE HIGHLANDS IN TAJIKISTAN
  8. EVALUATION OF HELICOBACTER PYLORI IN PATIENTS INVOLVED TO CHRONIC DYSPEPSIA
  9. COMPARATIVE ASSESSMENT OF ANEMIC SYNDROME IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA ON THE BACKGROUND TO THE GLEEVEC AND HYDREA THERAPY
  10. FEATURES OF FREE RADICAL OXIDATION AND METABOLIC ACTIVITY OF VASCULAR ENDOTHELIUM IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

◄ Back to the list